REVELATION BIOSCIENCES, INC. (REVB): Nasdaq/NYSE listing notice — Revelation Biosciences receives Nasdaq delisting notice for bid price non-compliance

REVELATION BIOSCIENCES, INC.

Received Nasdaq notice on Dec. 6, 2022, for failing to maintain $1.00 minimum bid price.
180-day grace period expired Dec. 5, 2022; a separate basis for delisting has been identified.
Company will provide a compliance plan to Nasdaq Hearings Panel and has requested a hearing.
Trading continues on Nasdaq under REVBU, REVB, and REVBW while review is pending.
No assurance that extension or continued listing will be granted.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

REVELATION BIOSCIENCES, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 6, 2022, Revelation Biosciences, Inc. (the “Company”) received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) which requires listed companies to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. Upon the expiration of that grace period, on December 5, 2022, the Company rece

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

REVELATION BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-026382

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.